A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Oncolys Aims to Bring Nucleocapsid Inhibitor into Clinic Next Year for COVID-19 Treatment
October 6, 2021
-
REGULATORY Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
-
REGULATORY New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
-
REGULATORY No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
-
ORGANIZATION FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
-
BUSINESS Sumitomo Dainippon, Otsuka Ink Global Collaboration for 4 Neuropsychiatric Drugs
October 1, 2021
-
REGULATORY Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
-
ORGANIZATION FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
-
COMMENTARY 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
-
BUSINESS Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
-
REGULATORY Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More
September 28, 2021
-
REGULATORY Japan Approves GSK’s COVID-19 Antibody Drug, 2nd Treatment for Mild Cases
September 28, 2021
-
ORGANIZATION Chuikyo Payer Rep Wants to Cut into Cost-Based Method, Adjustment Rate, Off-Year Revision in FY2022 Reform, Eyes Special Rules for Aducanumab
September 27, 2021
-
BUSINESS Startup Headed by Ex-Biogen Japan Chief Working to Develop New Alzheimer’s Drugs Using Photocatalysts
September 27, 2021
-
REGULATORY One-Month Business Suspension Order Likely for Choseido over Generic Recalls
September 24, 2021
-
BUSINESS Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
-
BUSINESS Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
-
ORGANIZATION JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
-
REGULATORY GSK/Vir’s COVID-19 Drug Up for MHLW Panel Review on Sept. 27
September 22, 2021
-
BUSINESS New Heart Failure Drugs Jostling with Different Modes of Action, Offering Variety of Options
September 21, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…